• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Quick Take: Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

byDonna LeetandAliya Ramjaun
December 16, 2018
in Cardiology, Chronic Disease, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke

The risk of venous thromboembolism (VTE) is significantly increased in patients with active cancer. While parenteral prophylactic anticoagulation has been shown to reduce the risk of VTE in cancer patients, its use is associated with an increased risk of major bleeding and the inconvenience of daily injections. Direct oral anticoagulants (DOACs) offer important advantages over parenteral agents, with a recent phase 2 trial suggesting that apixaban, an oral factor Xa inhibitor, may be used safely and effectively in this patient population. In this randomized controlled trial, 574 patients with newly diagnosed cancer or progression of known cancer starting a new course of chemotherapy were randomly assigned to receive twice daily apixaban (2.5 mg) or placebo to study the impact on the incidence of VTE within the first 180 days of treatment. Researchers found that the incidence of VTE was significantly less in the apixaban group (4.2%) compared to the placebo group (10.2%) (HR 0.41, 95% CI 0.26 to 0.65, p<0.001). During the treatment period, VTE was also less frequent in the apixaban group (1.0%) compared to the placebo group (7.3%) (HR 0.14, 95% CI 0.05 to 0.42). In the modified intention-to-treat analysis, major bleeding was more common in the apixaban group (HR 2.00, 95% CI 1.01 to 3.95, p=0.046). However, during the treatment period, there was no significant difference in rates of major bleeding between the two groups (HR 1.89, 95% CI 0.39 to 9.24). In summary, results from this study indicate that apixaban may reduce the rate of VTE in cancer patients initiating chemotherapy, although not without an increased rate of bleeding events when compared to placebo.

Click to read the study in NEJM

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationapixibanmajor bleedingVTEXa inhibitor
Previous Post

Quick Take: Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women

Next Post

AAP recommends pediatricians screen for postpartum depression

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

November 29, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Chronic Disease

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

October 19, 2022
No obesity paradox found between BMI, stroke, and death
Cardiology

Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke

October 4, 2022
#VisualAbstract: Nirmatrelvir associated with improved COVID-19 outcomes in older adults
StudyGraphics

#VisualAbstract: Aspirin associated with significantly higher rate of symptomatic venous thromboembolism compared to enoxaparin in patients undergoing hip or knee arthroplasty

September 8, 2022
Next Post
Prenatal antidepressant exposure may increase risk of poor motor development

AAP recommends pediatricians screen for postpartum depression

Targeted electronic health record reminder can reduce telemetry duration

Targeted electronic health record reminder can reduce telemetry duration

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options